By Billy Candra 
A pivotal new study by researchers at the Sloan Kettering Institute (SKI) at Memorial Sloan Kettering Cancer Center (MSK) has unveiled a long-standing mystery surrounding regulatory T (Treg) cells in colorectal cancer (CRC). For decades, the presence of large numbers of these immune cells, typically known to suppress the immune system and worsen outcomes in most solid tumors, presented a confounding paradox in CRC: higher Treg counts often correlated with improved patient survival. This perplexing exception to a widely observed oncological rule has now been comprehensively explained, with the discovery that not all Treg cells are created equal, and their distinct subtypes play opposing roles within the colorectal tumor microenvironment. This breakthrough, detailed in the scientific journal Immunity, promises to significantly advance immunotherapy strategies, particularly for the most common forms of CRC, and potentially extend to other cancers arising in barrier tissues like the skin, stomach, mouth, and throat.
The Immune Paradox in Colorectal Cancer
Regulatory T cells are a critical component of the immune system, primarily responsible for maintaining immune tolerance. Discovered in the late 1990s, these cells act as "brakes," preventing the immune system from launching unwarranted attacks on the body’s own healthy tissues, beneficial microbes, and everyday environmental exposures. In the context of cancer, however, their immunosuppressive function generally works against the host, hindering the body’s ability to mount an effective anti-tumor response. Consequently, an abundance of Tregs within the tumor microenvironment is typically associated with a poorer prognosis across a wide spectrum of cancers, including melanoma, lung cancer, and breast cancer, where they actively dampen the activity of cancer-fighting T cells.
Colorectal cancer, which tragically stands as the second leading cause of cancer-related death when men and women are considered together, has long defied this established paradigm. Clinical observations repeatedly showed that patients with a higher infiltration of Tregs in their colorectal tumors paradoxically experienced longer survival times. This anomaly has puzzled immunologists and oncologists, limiting the development of effective Treg-targeting therapies for CRC, as a blanket approach to deplete all Tregs could potentially remove beneficial populations. The MSK team’s findings now resolve this enigma, revealing a nuanced cellular landscape where the specific kind of Treg cell, rather than merely its quantity, dictates its impact on tumor progression.
Decades of Inquiry Culminate in a Breakthrough
The seminal work leading to this discovery is built upon more than two decades of dedicated research by Dr. Alexander Rudensky, Chair of the Immunology Program at MSK and a co-senior author of the study. Dr. Rudensky is a globally recognized authority on regulatory T cells, whose pioneering investigations have been instrumental in establishing the fundamental principles of Treg cell biology, including their development, functional mechanisms, and profound influence on both immune homeostasis and disease, including cancer. His lab’s foundational understanding of Treg cells provided the essential framework for this latest, more granular exploration.
The current study was spearheaded by a collaborative team of first authors: Dr. Xiao Huang, a postdoctoral researcher in the Rudensky Lab; Dr. Dan Feng, a former MSK Medical Oncology fellow now at the Icahn School of Medicine at Mount Sinai; and Dr. Sneha Mitra, a postdoctoral researcher in the lab of computational biologist Dr. Christina Leslie, the study’s other senior author. Their multidisciplinary approach, combining advanced immunological techniques with sophisticated computational analysis, was crucial for dissecting the complex cellular interactions within the tumor microenvironment.
Focusing on the Most Prevalent Colorectal Cancer Subtype
To maximize the clinical impact of their research, the MSK team concentrated their efforts on the most common form of colorectal cancer: microsatellite stable (MSS) tumors with proficient mismatch repair (MMRp). This subtype accounts for a substantial 80% to 85% of all CRC cases. Unfortunately, MSS-MMRp colorectal cancers are notoriously challenging to treat with current checkpoint inhibitor immunotherapies. Unlike tumors characterized by high microsatellite instability (MSI-H) and mismatch repair deficiency (MMRd), which often exhibit a robust response to immunotherapy, allowing many patients to avoid more aggressive treatments like surgery, chemotherapy, and radiation, MSS-MMRp tumors typically show minimal or no benefit from these groundbreaking treatments. This disparity underscores an urgent need for novel therapeutic strategies for the majority of CRC patients. The potential to leverage an understanding of Treg subtypes to enhance immunotherapy in this large, underserved patient population represents a significant leap forward.
The Discovery of Two Opposing Treg Subtypes
To unravel the unique immune dynamics of common colorectal cancers, the researchers employed a sophisticated mouse model meticulously developed at MSK. This model faithfully recapitulates the genetic alterations, behavioral patterns, and intricate immune environment observed in human colorectal tumors, providing a powerful platform for mechanistic investigation.
Their detailed analysis revealed that tumor-associated Treg cells do not represent a monolithic population but rather coalesce into two functionally distinct groups. The key differentiator identified was the production of interleukin-10 (IL-10), a cytokine known for its immunomodulatory properties.
-
IL-10-positive Treg cells: These cells were found to actively slow down tumor growth. Their mechanism involves reducing the activity of Th17 cells, another immune cell type that produces interleukin-17 (IL-17). IL-17, in turn, acts as a potent growth signal for tumors, promoting their proliferation and survival. These beneficial IL-10-positive Treg cells were predominantly located in the healthy tissue immediately adjacent to the tumor, suggesting a protective role in maintaining tissue homeostasis and perhaps preventing early tumor progression. Crucially, when these IL-10-positive Treg cells were selectively removed in experimental models, tumors exhibited accelerated growth, confirming their anti-tumorigenic function.
-
IL-10-negative Treg cells: In stark contrast, these cells exerted a detrimental effect on tumor control. They were observed to suppress powerful anti-cancer immune defenders, most notably CD8+ T cells, which are widely recognized for their direct cytotoxic capabilities against tumor cells. This harmful subtype was found primarily within the tumor mass itself, suggesting a direct role in creating an immunosuppressive microenvironment that shields cancer cells from immune attack. The elimination of these IL-10-negative Treg cells resulted in a significant reduction in tumor size, unequivocally demonstrating their pro-tumorigenic role.
This revelation fundamentally redefines the understanding of Treg function in CRC. "Instead of the regulatory T cells promoting tumor growth, as they do in most cancers, in colorectal cancer we discovered there are actually two distinct subtypes of Treg cells that play opposing roles — one restrains tumor growth, while the other fuels it," explained Dr. Alexander Rudensky. "It’s these beneficial Treg cells that make the difference, and this underscores the need for selective approaches."
Validation in Human Colorectal Cancer Patients
To ensure the translational relevance of their findings, the research team meticulously validated their observations using human tumor samples obtained from colorectal cancer patients. Consistent with their mouse model data, they successfully identified two distinct populations of IL-10-positive and IL-10-negative Treg cells within these human samples.
Further strengthening the clinical implications, the researchers analyzed the outcomes of over 100 colorectal cancer patients. The results were compelling: patients whose tumors harbored higher levels of the beneficial IL-10-positive Treg cells exhibited significantly longer survival. Conversely, patients whose tumors contained a greater proportion of the harmful IL-10-negative Treg cells experienced poorer clinical outcomes. This robust correlation between Treg subtype prevalence and patient prognosis provides strong evidence that the dual nature of Tregs is a critical determinant of disease progression in human CRC. "This research shows how important these positive cells are," stated Dr. Huang. "And it highlights the need to develop therapies that can selectively eliminate the harmful Tregs while preserving the helpful ones."
A New Therapeutic Frontier: Targeting CCR8
The insights gleaned from this study offer a promising and actionable path forward for improving treatment for the vast majority of colorectal cancer patients. The researchers identified a key molecular marker on the harmful IL-10-negative Treg cells: high expression of a protein called CCR8. These are precisely the cells that actively suppress the immune response and are predominantly localized within the tumor itself.
The concept of targeting CCR8 is not entirely new to MSK. Earlier foundational work from Dr. Rudensky’s lab, led by breast cancer surgeon Dr. George Plitas, had previously shown that CCR8 is highly expressed on tumor-infiltrating Treg cells in breast cancer and numerous other human malignancies. That pioneering research laid the groundwork for the hypothesis that therapeutic antibodies could be designed to selectively deplete these harmful CCR8-expressing Treg cells. Such a targeted approach would allow the body’s immune system to mount a more effective attack against tumors, crucially without compromising the beneficial Treg populations that are essential for maintaining overall immune homeostasis and preventing autoimmunity.
"This idea of using CCR8-depleting antibodies, which was pioneered at MSK, is the main target of global efforts to bring regulatory T cell-based immunotherapy to the clinic," emphasized Dr. Rudensky, who is also a Howard Hughes Medical Institute Investigator. This underscores the significance and foresight of MSK’s research in this area. Several clinical trials are currently underway at MSK and other leading institutions worldwide, rigorously evaluating this CCR8-targeting strategy, both as a monotherapy and in combination with existing immunotherapies. The compelling new data from the colorectal cancer study provides strong additional rationale and momentum for advancing this strategy, not only for CRC but potentially for a broader range of cancers.
Broader Implications: Beyond Colorectal Cancer to Barrier Tissues
The MSK team extended their analysis beyond colorectal cancer, examining a vast dataset of T cells derived from 16 different cancer types. Their investigation aimed to ascertain whether the unique immune patterns observed in CRC – specifically, the division between IL-10-positive and IL-10-negative Treg cells – might manifest in other malignancies. Remarkably, they found similar dichotomies in several cancers affecting barrier tissues, including the skin and the lining of the mouth, throat, and stomach.
"What these tissues have in common is that immune cells play a critical role in constantly defending and repairing them as they’re exposed to microbes and environmental stresses," explained Dr. Mitra, who spearheaded the intricate data analysis. This shared characteristic suggests a fundamental immunological principle at play: in tissues constantly interacting with the external environment, a delicate balance of immune regulation is crucial. The presence of protective Treg subtypes may be essential for preventing chronic inflammation and autoimmune responses in these vulnerable sites, while specific detrimental subtypes contribute to immune evasion by tumors. This expanded understanding implies that therapeutic strategies designed to remove IL-10-negative Treg cells in colorectal cancer could potentially be effective against these other barrier tissue cancers, opening avenues for broader clinical application.
A Different Immune Balance in Metastatic Disease
The research also provided critical insights into the dynamics of metastatic colorectal cancer. When the team investigated CRC that had spread to the liver, a common site of metastasis, they observed a notably different immune pattern. In these metastatic tumors, the harmful IL-10-negative Treg cells significantly outnumbered the beneficial IL-10-positive cells. Furthermore, unlike primary tumors, the complete removal of all Treg cells in this metastatic context led to a reduction in tumor size. This finding suggests that in advanced, metastatic disease, the balance shifts dramatically, with the overall Treg population becoming predominantly immunosuppressive. This crucial distinction highlights the necessity for treatment strategies to be tailored not only to the specific tissue involved but also to the stage of the disease, emphasizing the need for precision medicine approaches in oncology.
The Road Ahead: Clinical Trials and Future Research
The findings from the Sloan Kettering Institute represent a significant stride in the understanding and treatment of colorectal cancer, particularly the challenging MSS-MMRp subtype. By dissecting the heterogeneous nature of Treg cells, researchers have provided a clear explanation for a long-standing paradox and illuminated a promising therapeutic target in CCR8. The ongoing clinical trials evaluating CCR8-depleting antibodies are poised to translate these laboratory discoveries into tangible benefits for patients. The potential for these therapies to be effective in other barrier tissue cancers further amplifies the impact of this research.
Future investigations will undoubtedly delve deeper into the specific molecular mechanisms that drive the differentiation and function of these Treg subtypes, and how their balance might be modulated for therapeutic gain. Identifying biomarkers that can predict which patients will benefit most from CCR8-targeting therapies will also be crucial for optimizing treatment selection. The work from MSK exemplifies the power of sustained, foundational immunological research in revolutionizing cancer care, moving beyond broad classifications to a nuanced understanding of cellular roles within the complex tumor microenvironment.
Authors, Funding, and Disclosures
Additional authors contributing to this impactful study include Emma Andretta, Nima Hooshdaran, Aazam Ghelani, Eric Wang, Joe Frost, Victoria Lawless, Aparna Vancheswaran, Qingwen Jiang, Cheryl Mai, and Karuna Ganesh. Critical support for the research was provided by the Integrated Genomics Operation and the Single Cell Research Initiative at MSK. Funding for this extensive project was generously provided by multiple organizations, including the National Cancer Institute (P30 CA008748, U54 CA274492, T32 CA009512), the National Institute of Allergy and Infectious Diseases (AI034206), the Ludwig Center for Cancer Immunotherapy at MSK, the Howard Hughes Medical Institute, the Cancer Research Institute, and a Marie-Josée Kravis Fellowship in Quantitative Biology.
Dr. Rudensky maintains various affiliations, serving on scientific advisory boards and holding equity in Sonoma Biotherapeutics, RAPT Therapeutics, Coherus Oncology, Santa Ana Bio, Odyssey Therapeutics, and Nilo Therapeutics. He is also a scientific advisory board member of Amgen, BioInvent, and Vedanta Biosciences, has consulted for AbbVie, and serves as an editor of the Journal of Experimental Medicine and an editorial advisor to Immunity. Importantly, Dr. Rudensky and Dr. Plitas are recognized as inventors on patents and patent applications held by MSK, which are directly related to CCR8-based therapeutic depletion of tumoral Treg cells and the development of novel antibodies targeting CCR8, highlighting the innovative nature and translational potential of their research.
